30 completed. 30 Phase 2, 7 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 30 |
| Phase 1 | 7 | Completed 7 |
| Phase 3 | 7 | Completed 7 |
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B - Influenza, SARS-CoV-2 | Phase 2 | Completed | ModernaTX, Inc. | 1320 | 2025-03-07 | 2025-10-20 |
| A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) mRNA-1083 - Influenza, SARS-CoV-2 | Phase 2 | Completed | ModernaTX, Inc. | 931 | 2024-07-15 | 2026-10-08 |
| PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19 Upamostat, Placebo (PO) - SARS-CoV-2 | Phase 2 | Completed | Henry M. Jackson Foundation for the Advancement of Military Medicine | 92 | 2024-01-29 | 2026-04-17 |
| A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose) - SARS-CoV-2, COVID-19 | Phase 2 | Completed | GlaxoSmithKline | 692 | 2023-08-01 | 2025-10-23 |
| A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 1758 | 2023-04-14 | 2025-12-23 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old mRNA-1073, mRNA-1010, mRNA-1273 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 550 | 2022-05-13 | 2024-02-28 |
| Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People SARS-CoV-2 (LVRNA009) 50μg group, SARS-CoV-2 (LVRNA009) 100μg group, Placebo - SARS-CoV-2 | Phase 2 | Completed | AIM Vaccine Co., Ltd. | 420 | 2022-03-16 | 2023-09-06 |
| A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 mRNA-1273.529, mRNA-1273, mRNA-1273.214 - SARS-CoV-2 | Phase 2 / Phase 3 | Completed | ModernaTX, Inc. | 3548 | 2022-02-16 | 2024-08-09 |
| A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults RBMRNA-176, Placebo - SARS-CoV-2 | Phase 1 / Phase 2 | Completed | Argorna Pharmaceuticals Co., LTD | 480 | 2022-01-08 | 2024-01-10 |
| Convalescent Plasma Therapy for Hospitalized Patients With COVID-19 Convalescent plasma, Standard of care - COVID-19, Convalescent Plasma | Phase 2 | Completed | Tânia Portella Costa | 38 | 2022-01-06 | 2023-11-29 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters mRNA-1283, mRNA-1283.211, mRNA-1273 - SARS-CoV-2 | Phase 2 | Completed | ModernaTX, Inc. | 540 | 2021-12-06 | 2025-07-17 |
| Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults AZD1222, AZD2816 - COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | Completed | AstraZeneca | 2843 | 2021-06-27 | 2024-09-19 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants mRNA-1273.211, mRNA-1273, mRNA-1273.617.2 - SARS-CoV-2 | Phase 2 / Phase 3 | Completed | ModernaTX, Inc. | 5161 | 2021-05-28 | 2025-02-28 |
| A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults Covigenix VAX-001 placebo, Covigenix VAX-001 - SARS-CoV-2 | Phase 1 / Phase 2 | Completed | Entos Pharmaceuticals Inc. | 268 | 2021-04-07 | 2024-02-20 |
| A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age mRNA-1273, Placebo, mRNA-1273.214 - SARS-CoV-2 | Phase 2 / Phase 3 | Completed | ModernaTX, Inc. | 11942 | 2021-03-15 | 2025-06-13 |
| Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19) Alisporivir, Standard of care (SOC) - SARS-CoV-2 | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 26 | 2021-01-08 | 2023-05-11 |
| GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19) GLS-5310, Placebo - SARS-CoV-2 | Phase 1 / Phase 2 | Completed | GeneOne Life Science, Inc. | 171 | 2020-12-31 | 2025-09-03 |
| Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults GX-19N, Placebo - SARS-CoV-2 | Phase 1 / Phase 2 | Completed | Genexine, Inc. | 185 | 2020-12-30 | 2025-08-20 |
| A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older CVnCoV, Placebo, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program - Covid19, SARS-CoV-2 | Phase 2 / Phase 3 | Completed | CureVac | 39680 | 2020-12-11 | 2024-04-29 |
| A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 mRNA-1273, Placebo, mRNA-1273.222 - SARS-CoV-2 | Phase 2 / Phase 3 | Completed | ModernaTX, Inc. | 4328 | 2020-12-09 | 2025-09-15 |
Showing 20 of 30. Sign in to see all of them.
COVID-19 (22) · Coronavirus Infections (12) · Virus Diseases (6) · Influenza, Human (4) · Severe Acute Respiratory Syndrome (3) · Pneumonia (1) · Respiratory Tract Diseases (1)
Infections (25) · RNA Virus Infections (25) · Respiratory Tract Infections (25) · Respiratory Tract Diseases (24) · Coronaviridae Infections (23) · Nidovirales Infections (23) · Lung Diseases (22) · Pneumonia, Viral (22) · Pneumonia (21) · Virus Diseases (19) · Coronavirus Infections (11) · Orthomyxoviridae Infections (4)
2019-nCoV Vaccine mRNA-1273 (6) · Standard of Care (3) · mRNA-1273.214 COVID-19 vaccine (3) · CVnCoV COVID-19 vaccine (2) · Ascorbic Acid (1) · BNT162 Vaccine (1) · Baiya SARS-CoV-2 VAX COVID-19 vaccine (1) · COVID-19 Vaccines (1) · ChAdOx1 nCoV-19 (1) · GLS-5310 vaccine (1) · GX-19N vaccine (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Hepatitis A Vaccines (1) · Hydroxychloroquine (1) · Influenza Vaccines (1)
ModernaTX, Inc. (10) · CureVac (2) · AIM Vaccine Co., Ltd. (1) · Arcturus Therapeutics, Inc. (1) · Argorna Pharmaceuticals Co., LTD (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · BioNTech SE (1) · Blade Therapeutics (1) · Entos Pharmaceuticals Inc. (1) · GeneOne Life Science, Inc. (1) · Genexine, Inc. (1) · GlaxoSmithKline (1) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1) · King Abdulaziz University (1)
United States (15) · Brazil (3) · Canada (3) · China (3) · South Africa (3) · United Kingdom (3) · Dominican Republic (2) · Panama (2) · Peru (2) · South Korea (2) · Argentina (1) · Australia (1) · Belgium (1) · Burkina Faso (1) · Colombia (1)
Jenny Low Guek Hong, MD (1) · Joakem Tazanu Fossung (1) · Jun Yong Choi, MD (1) · JungWon Woo, Ph.D. (1) · Kengi Itinose, MD (1) · Nick Francis (1) · Ruanne V. Barnabas, MBChB, DPhil (1) · Tao Huang (1) · Tom Wilkinson (1)
PMID 32493478, PMID 32771034, PMID 32788708, PMID 33189161, PMID 33284679, PMID 33707061, PMID 34379915, PMID 34407441, PMID 34526698, PMID 34826381, PMID 34870630, PMID 35156068, PMID 35241844, PMID 35291289, PMID 35544369, PMID 36112399, PMID 36120090, PMID 36202997, PMID 36238717, PMID 36260859, PMID 36376733, PMID 36458916, PMID 37348519, PMID 37653342, PMID 37703353, PMID 37783221, PMID 38518789, PMID 38878794, PMID 39158584, PMID 39332418, PMID 39383382, PMID 39481241, PMID 39792478, PMID 40102593, PMID 40119775, PMID 41627968, PMID 42647564
2023 (1)